Title: Dazoxiben: a pharmacological tool or clinical candidate?
Abstract: British Journal of Clinical PharmacologyVolume 15, Issue S1 p. 13S-16S Free Access Dazoxiben: a pharmacological tool or clinical candidate? HM Tyler, HM TylerSearch for more papers by this author HM Tyler, HM TylerSearch for more papers by this author First published: February 1983 https://doi.org/10.1111/j.1365-2125.1983.tb02101.xCitations: 21AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References BELCH, J.J.F., NEWMAN, P., DRURY, J.K., CAPELL, H., LEIBERMAN, P., JAMES, W.B., FORBES, C.D., & PRENTICE, C.R.M. (1981). Successful treatment of Raynaud's Syndrome with prostacyclin. Thromb. Haemostas., 45(3), 255– 256. CARLSON, L.A. & OLSSON, A.G. (1979). PGE1 in ischaemic peripheral vascular disease. In The Practical Applications of Prostaglandins and their Synthesis Inhibitors, ed. S.M.M. Karim, pp. 39– 51. Lancaster. MTP Press. CLIFFORD, P.C., MARTIN, M.F.R., SHEDDON, E. JANE, KIRBY, J.D., BAIRD, R.N. & DIEPPE, P.A. (1980). Treatment of vasospastic disease with prostaglandin E1 Br. med. J., 2, 1031– 1034. COKER, S.J., LEDINGHAM, I. MCA., PARRAT, J.R. & ZEITLIN, I.J. (1982). Ventricular fibrillation resulting from reperfusion of the acutely ischaemic canine myocardium is prevented by the thromboxane synthetase inhibitor UK-37, 248. Scot. Med. J., 27, 193. COOK, J. A., HALUSHKA, P.V. & WISE, W.C. (1981). Effect of the thromboxane (Tx)A2 synthetase inhibitor, UK-37, 248, in endotoxin (LPS) shock: Improved functional parameters and prevention of splanchnic infarction. Physiologist., 24, 110. DA VIES, J.A. & MENYS, V.C. (1981). Concentration of TXB2 and 6-oxo-PGFl in relation to adhesion of rabbit platelets to damaged aorta. Eur. Heart. J., 2, suppl. A, 211. HIRSH, P.D., HILLIS, L.D., CAMPBELL, W.B., FIRTH, B.G., & WILLERSON, J.T. (1981). Release of prostaglandins and thromboxane into the coronary circulation in patients with ischaemic heart disease. New Engl. J. Med., 304, No. 12, 685– 691. HUTTON, I., TWEDDEL, A.C., RANKIN, A.C., WALKER, ISOBEL D., & DAVIDSON, J.F. (1981). Evaluation of selective thromboxane synthetase inhibitor in patients with coronary heart disease. Circulation, 64, No. 4, pt. 2, abstr. 10. KIFF, P.S., BERGMAN, G.W., WESTWICK, J., ATKINSON, L., KAKKAR, V.V. & JEWITT, D.E. (1982). The release of thromboxane during atrial pacing and the haemodynamic and metabolic effects of its inhibition by dazoxiben. Am. J. Cardiol., 14, 902. KNUDSEN, J.B., JUHL, A. & GORMSEN, J. (1981). Thromboxane synthetase inhibition in patients with atherosclerotic heart disease. Lancet., 2, 198. LEWY, R.I., WIENER, L., WALINSKY, P., LEFER, A.M., SILVER, M.J. & SMITH, J.B. (1980). Thromboxane release during pacing-induced angina pectoris: possible vasoconstriction influence on the coronary vasculature. Circulation., 61, No. 6, 1165– 1170. MCGIBNEY, D., MENYS, V.C., NELSON, G.I.C., KUMAR, E.B., TAYLOR, S.H., & DAVIES, J.A. Effects of UK-37, 248, a thromboxane synthetase inhibitor, on platelet behaviour in patients with coronary heart disease undergoing exercise to angina. Clin. Sci., 62, 12p. MONCADA, S. & VANE, J.R. (1979). Pharmacology and endogenous roles of prostaglandin endoperxides, thromboxane A2, and prostacyclin. Pharmac. Rev., 30, No. 3, 293– 331. NEEDLEMAN, P., WYCHE, A. & RAZ, A. (1979). Platelet and blood vessel arachidonate metabolism and interactions. J. clin. Invest., 63, 345– 349. OLSSON, A.G. & NILSSON, E. (1981). The effect of intravenous prostacyclin on resting pains and healing of ischaemic ulcers in peripheral artery disease. Prostaglandins and Medicine, 6, 329– 339. PARRY, M.J., RANDALL, M.J., TYLER, H.M., MYHRE, E., DALE, J. & THAULOW, E. (1982). Selective inhibition of thromboxane synthetase by dazoxiben increases prostacyclin production by leucocytes in angina patients and healthy volunteers. Lancet, 2, 164. RANDALL, M.J., PARRY, M.J., HAWKESWOOD, E., CROSS, P.E. & DICKINSON, R.P. (1981). UK-37248, a novel, selective thromboxane synthetase inhibitor with platelet antiaggregatory and anti-thrombotic activity. Thromb. Res., 23, 145– 162. TADA, M., KUZUYA, T., INOVE, M., KODAMA, K., MISHIMA, M., YAMADA, M., INVI, M. & ABE, H. (1981). Elevation of thromboxane B2 levels in patients with classic and variant angina pectoris. Circulation, 64, No. 6. 1107– 1115. TYLER, H.M., SAXTON, C.A.P.D. & PARRY, M.J. (1981). Administration to man of UK-37, 248-01, a selective inhibitor of thromboxane synthetase. Lancet, 1, 629– 632. WEBB, P.J., WESTWICK, J., SCULLY, M.F., ZAHAVI, J. & KAKKAR, V.V. (1981). Do prostacyclin and thromboxane play a role in endotoxic shock? Br. J. Surg., 68, 720– 724. ZIMMERMAN, R., PETER, J., JUNG, G., HORSCH, A., MORL, H. & HARENBERG, J. (1981). Anti-thrombotic and opposite effects of drugs influencing the prostacyclin system. Thromb. Haemostas., 46(1), 179. Citing Literature Volume15, IssueS1February 1983Pages 13S-16S ReferencesRelatedInformation